Company Presentation · Company Presentation February 2019. Agenda 01 Sartorius Stedim Biotech in...

1

Company PresentationFebruary 2019

Agenda

Sartorius Stedim Biotech in Brief01

03 Sartorius Stedim Biotech 2020 and 2025

Total Solutions Provider for the Biopharma Industry02

Sartorius Stedim Biotech in 2018

Figures as of Dec. 31, 2018; 1 Underlying EBITDA ( )excluding extraordinary items 2 As of end of December, 2018; including SSB free float 3

Bioprocess Technologies Provider

Internationally leading

~35%Americas

~42%EMEA

~23%Asia | Pacific

Publicly listed since 1990

~€342 mnEarnings1

>€1.21 bnSales revenue

Earnings1 margin

~€177 mnInvestments

28.2%

Sales revenue by region

~€8.1 bnMarket capitalization2

Around 5,600 employees worldwide

Figures as of Dec. 31, 2018 5

~ 880Americas

~4,000EMEA

~750Asia|Pacific

Employees by Regions Employees growth 2012-2018

~+70%

2013

2018

Our corporate values

6

Agenda




8

Solution provider for biomanufacturing

Highly regulated environment |validated processes

Broadest portfolio in the industry

Unique position in an attractive market

What are biopharmaceuticals?

R&D and production labor-intensive

High therapy costs: biologics ~ $50 vs. chemical medications ~ $2 per day

Living, geneticallymodified Cells Production Injection | Infusion

Advantages Challenges

First-time or improved treatment of serious illnesses, such as cancer, multiple sclerosis, rheumatism Targets only diseased cells; fewer side effects New vaccines

9

Focusing on Biopharma for more than 15 years

Molecule developmentCell line and process development

Productionupstream & downstream

Lab Products & Services Division

10

Bioprocess Solutions Division

Quality & testing

Driven by strong fundamentals, Biopharma is a growth market

11

+6.4%CAGR

of worldwideprescription drugsales 2018-2024

9 bnpeople by 2050

of which >2 bn60yrs or older

Rise of biosimilars

>30%CAGR of

biosimilar sales2018-2022

Favorable R&D pipeline; strongadvances in gene and cell therapy

~8%CAGR of biopharma market

2018-2025

>40%Share of biologicsin pharma R&D

pipeline

Favorable demographics Increasing healthcare spending

Well positioned as a Total solution provider across the Biopharma process chain

Fermentation Cell Harvesting Buffer | PreparationCell Culture Media

12

Process Development Production

Services

Purification

High initial cost

Considerable cleaning effort

Risk of cross-contamination

13

Pioneer in single-use manufacturing technologies

PresentPast

+ CAPEX reduction over entire lifecycle

+ Lower water and energy consumption

+ Higher flexibility

Around 75% of recurrent business with single-use products

~ €1,21 bnSingle-use~ 75 %

Equipment~25 %

14Figures as of Dec. 31, 2018

>85% of sales revenue generated from top 1-3 positions

Filtration TOP 3 Fluid Management #1 Fermentation #1

Leading market positions worldwide

15

Agenda




On track to deliver on our 2020 goals that were set in 2011

17Figures as of Dec 31, 2018. Sales growth and CAGR in constant currencies 2 Based on Guidance1 Excluding extraordinary items

Sales revenue EBITDA1 margin in %

20.9 21.523.0 23.5

26.227.5 27.3 28.2 +~1pp ~29-30 ~30

151617181920212223242526272829303132333435363738394041424344454647484950

0

200

400

600

800

1000

1200

1400

1600

1800

2000

2200

2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2025

€477 mn

€1.2 bn

~€1.5 bn

~€2.8 bn

+13.7%+4.1%

+20.4%+19.4%

+15.9%+10.8%

+10.3%

~+7-11%

2 2 2

Cell line developmentservices Q3 2015

Testing in biosafety andbioanalytics Q2 2015

Small-scale single-use bioreactors Q4 2013

Cell culture mediaQ1 2013

Single-use technologyfor samplingQ2 2014

Portfolio continuously enhanced via strategic acquisitions

18

Process Development Production

Software for bioprocessdata analysisQ2 2017

Single-usecentrifugesQ3 2016

Infrastructure prepared for further growth

19

Capex ratio

New ERP and extension of globalIT infrastructure

Goettingen, Germany: Extension

Aubagne, France: Capacity extension ofbag production

Yauco, Puerto Rico: Doubling of fluid management and filter capacities ~15%

Our Growth Targets Up to 2025

2025 ambition is based on 2017 currency exchange rates; non-organic revenue growth is accounted for companies acquired from 2018onwards; EBITDA excluding extraordinary items

Regional

Participate in strong Chinese market growth Continue to outgrow the important U.S. market

Strategic Initiatives 2025 Targets

Portfolio

Adding high-impact innovation, e.g. digital tools Enhance process development capabilities Expand into adjacent applications

Operations

Accelerate workflows across the organization through digitalization Extend manufacturing base in Asia

20

~€2.8 bnSales revenue

~30% EBITDA margin

Thank you very muchfor your attention

Disclaimer

This presentation contains statements concerning Sartorius Stedim Biotech Groups’ future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

Scalable products from process development to productionFermentation | Cell culture

BIOSTAT® RM

0.1 up to 300 liters

UniVessel® SU

0.6 up to 2 liters

BIOSTAT STR®

12.5 up to 2,000 liters

ambr®

15 up to 250 ml

23

Scalable products from process development to productionSartobind® membrane adsobers (Purification)

nano mini 10“ 20“ 30“ Jumbo5“pico

24

Scalable products from process development to productionFluid Management

Flexsafe® &Flexboy® Bags

50 millilitersup to 50 liters

Flexsafe® & Flexel®

100 up to 3,000 liters

Celsius®-Pak

30 millilitersup to 16.6 liters

Flexsafe ® & Flexel® for Mixer

50 up to 3,000 liters

25

Company Presentation · Company Presentation February 2019. Agenda 01 Sartorius Stedim Biotech in...

Documents

Transcript of Company Presentation · Company Presentation February 2019. Agenda 01 Sartorius Stedim Biotech in...